Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687420 | 1.00 | TRPV3 (0.60) | TRPV3GPR119MAPTCNR1NPSR1 | |
| SCHEMBL2878345 | 0.81 | TRPV3 (0.53) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL29491422 | 0.81 | TRPV3 (0.53) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL16291592 | 0.80 | GPR119 (0.50) | TRPV3GPR119MAPTNPSR1KDM4E | |
| SCHEMBL29518419 | 0.80 | GPR119 (0.50) | TRPV3GPR119MAPTNPSR1KDM4E | |
| SCHEMBL15985053 | 0.79 | TRPV3 (0.51) | TRPV3GPR119MAPTNPSR1KDM4E | |
| SCHEMBL29161582 | 0.79 | TRPV3 (0.51) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL20266387 | 0.79 | POLB (0.53) | TRPV3GPR119MAPTKDM4ETHRB | |
| SCHEMBL21979953 | 0.79 | TRPV3 (0.54) | TRPV3GPR119MAPTCNR1NPSR1 | |
| SCHEMBL31639493 | 0.79 | THRB (0.50) | TRPV3GPR119MAPTNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145596-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-115667238-B | Five-membered ring derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4269399-A1 | FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023066356-A1 | COMPOUND AS GLP-1 RECEPTOR AGONIST AND USE THEREOF | 盛世泰科生物医药技术(苏州)有限公司 | 2023-04-27 | — | — | WO | disclosed |
| CN-115667238-A | Five-membered ring derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022109182-A9 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022135572-A1 | FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022135572-A1 | FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2022109182-A1 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022078407-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | TRPV3 1148/4885GPR119 3/4885MAPT 3314/4885 |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TRPV3 410/4885GPR119 11/4885MAPT 3873/4885 |
| US-20250145596-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TRPV3 833/4885GPR119 5/4885MAPT 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.